Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998–2018

• Published in: BMC public health Vol. 22; no. 1; pp. 1 - 1677
• Main Authors: Hu, Tianyan, Song, Yan, Done, Nicolae, Liu, Qing, Sarpong, Eric M, Lemus-Wirtz, Esteban, Signorovitch, James, Mohanty, Salini, Weiss, Thomas
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 05.09.2022; BioMed Central; BMC
• Subjects: Age; Arthritis; Bacteremia; Children; Codes; Conjugates; Disease control; Disease prevention; Drug dosages; Endocarditis; FDA approval; Forecasts and trends; Government programs; Immunization; Incidence rate estimates; Influence; Invasive pneumococcal disease; Medicaid; Medicare; Meningitis; Morbidity; Pediatrics; Peritonitis; Pneumococcal conjugate vaccines; Pneumococcal infections; Pneumococcal vaccine; Pneumonia; Public health; Risk analysis; Risk factors; Serotypes; Streptococcus infections; Surveillance; Trends; Vaccine efficacy; Vaccines; United States; United States > US

Abstract Background Invasive pneumococcal disease (IPD) is a major cause of pediatric morbidity and mortality. Pneumococcal conjugate vaccines (PCVs) were introduced in the US in 2000 (PCV7) and 2010 (PCV13). This study estimated the annual incidence rates (IRs) and time trends of IPD to quantify th...